A
Andreas Hüttmann
Researcher at University of Duisburg-Essen
Publications - 120
Citations - 4846
Andreas Hüttmann is an academic researcher from University of Duisburg-Essen. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 30, co-authored 102 publications receiving 3476 citations. Previous affiliations of Andreas Hüttmann include QIMR Berghofer Medical Research Institute & Eppendorf (Germany).
Papers
More filters
Journal ArticleDOI
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven M. Horwitz,Owen A. O'Connor,Barbara Pro,Timothy M Illidge,Michelle A. Fanale,Ranjana H. Advani,Nancy L. Bartlett,Jacob Haaber Christensen,Franck Morschhauser,Eva Domingo-Domenech,Giuseppe Rossi,Won Seog Kim,Tatyana Feldman,Anne Lennard,David Belada,Árpád Illés,Kensei Tobinai,Kunihiro Tsukasaki,Su-Peng Yeh,Andrei R. Shustov,Andreas Hüttmann,Kerry J. Savage,Sam Yuen,Swaminathan Padmanabhan Iyer,Pier Luigi Zinzani,Zhaowei Hua,Meredith Little,Shangbang Rao,Joseph Woolery,Thomas Manley,Lorenz Trümper +30 more
TL;DR: Front-line treatment with A+CHP is superior to CHOP for patients with CD30-positive peripheral T-cell lymphomas as shown by a significant improvement in progression-free survival and overall survival with a manageable safety profile.
Journal ArticleDOI
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.
Nicola Gökbuget,Daniel Stanze,Joachim Beck,Helmut Diedrich,Heinz-August Horst,Andreas Hüttmann,Guido Kobbe,Karl-Anton Kreuzer,Lothar Leimer,Albrecht Reichle,Markus Schaich,Stefan Schwartz,Hubert Serve,Michael Starck,Matthias Stelljes,Reingard Stuhlmann,Andreas Viardot,Knut Wendelin,Mathias Freund,Dieter Hoelzer +19 more
TL;DR: Overall survival appeared superior compared with previously published studies, likely because of the high rate of SCT in the present study (75%).
Journal ArticleDOI
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Christoph Röllig,Hubert Serve,Andreas Hüttmann,Richard Noppeney,Carsten Müller-Tidow,Utz Krug,Claudia D. Baldus,Christian Brandts,Volker Kunzmann,Hermann Einsele,Alwin Krämer,Kerstin Schäfer-Eckart,Andreas Neubauer,Andreas Burchert,Aristoteles Giagounidis,Stefan W. Krause,Andreas Mackensen,Walter E. Aulitzky,Regina Herbst,Mathias Hänel,Alexander Kiani,Norbert Frickhofen,Johannes Kullmer,Ulrich Kaiser,Hartmut Link,Thomas Geer,A. Reichle,Christian Junghanß,Roland Repp,Frank Heits,Heinz Dürk,Jana Hase,Ina-Maria Klut,Thomas Illmer,Martin Bornhäuser,Markus Schaich,Stefani Parmentier,Martin Görner,Christian Thiede,Malte von Bonin,Johannes Schetelig,Michael Kramer,Wolfgang E. Berdel,Gerhard Ehninger +43 more
TL;DR: This randomised, double-blind, placebo-controlled, phase 2 trial investigated the efficacy and tolerability of sorafenib versus placebo in addition to standard chemotherapy in patients with acute myeloid leukaemia aged 60 years or younger.
Journal ArticleDOI
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
David M. Kurtz,Florian Scherer,Florian Scherer,Michael C. Jin,Joanne Soo,Alexander F.M. Craig,Mohammad Shahrokh Esfahani,Jacob J. Chabon,Henning Stehr,Chih Long Liu,Robert Tibshirani,Lauren S. Maeda,Neel K. Gupta,Michael S. Khodadoust,Ranjana H. Advani,Ronald Levy,Aaron M. Newman,Ulrich Dührsen,Andreas Hüttmann,Michel Meignan,Rene-Olivier Casasnovas,Jason R. Westin,Mark Roschewski,Wyndham H. Wilson,Gianluca Gaidano,Davide Rossi,Davide Rossi,Maximilian Diehn,Ash A. Alizadeh +28 more
TL;DR: Pretreatment ctDNA levels and molecular responses are independently prognostic of outcomes in aggressive lymphomas, and these risk factors could potentially guide future personalized risk-directed approaches.
Journal ArticleDOI
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Peter Borchmann,Helen Goergen,Carsten Kobe,Andreas Lohri,Richard Greil,Dennis A. Eichenauer,Josée M. Zijlstra,Jana Markova,Julia Meissner,Michaela Feuring-Buske,Andreas Hüttmann,Judith Dierlamm,Martin Soekler,Hans Joachim Beck,Wolfgang Willenbacher,Wolf-Dieter Ludwig,Thomas Pabst,Max S. Topp,Felicitas Hitz,Martin Bentz,Ulrich Keller,Dagmar Kühnhardt,Helmut Ostermann,Norbert Schmitz,Bernd Hertenstein,Walter E. Aulitzky,Georg Maschmeyer,Tom Vieler,Hans Theodor Eich,Christian Baues,Harald Stein,Michael Fuchs,Georg Kuhnert,Volker Diehl,Markus Dietlein,Andreas Engert +35 more
TL;DR: This open-label, randomised, parallel-group phase 3 trial investigated whether metabolic response determined by PET after two cycles of standard regimen eBEACOPP (PET-2) would allow adaption of treatment intensity, increasing it for PET-2-positive patients and reducing it forPET- 2-negative patients and showed non-inferiority in the 5-year progression-free survival estimates.